PMV Pharmaceuticals, Inc.

Contributing Author

Recent Articles by PMV Pharmaceuticals, Inc.

Oct-24	PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation PMVP GlobeNewswire
Oct-13	PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics PMVP GlobeNewswire
Sep-10	PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation PMVP GlobeNewswire
Aug-07	PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights PMVP GlobeNewswire
May-23	PMV Pharmaceuticals to Participate at Upcoming Investor Conferences PMVP GlobeNewswire
May-09	PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights PMVP GlobeNewswire